Highlights
- Cost-effective and fast kit-based chemical platform to produce radiopharmaceuticals using existing radiopharmacy and nuclear medicine infrastructure
- Platform has theranostic potential, using 99mTc and 188Re radioisotopes for diagnostic imaging and molecular radiotherapy
- Widely applicable to many types of cancer
The Opportunity
Versatile diphosphine chelator 999mTc/188Re radiotracers have been formulated into simple kits for attachment to cancer-targeting peptides.
99mTc labels are widely used for perfusion tracing/functional imaging. Approximately 30 million routine 99mTc SPECT/y-scintigraphy procedures are completed annually worldwide.
Molecular targeting with PET/CT scanners is standard but expensive and logistically complex. By utilising molecularly-targeted agents with existing SPECT imaging infrastructure and onsite generators, this platform addresses the clinical need for economical and efficient imaging agents.
The platform has been validated in mouse models of inflammation and prostate cancer (PSMAt-radiotracers) and is being developed with a G-protein-coupled Receptor (CXCR4)-targeted peptide (for breast cancer), and Fibroblast Activation Protein Inhibitor (FAPI for hard-to -treat cancers).
Developed by Dr. Michelle Ma at King’s College London and Prof. Paul Pringle at University of Bristol.
For further information, contact
